title: Dendritic cell-based immunotherapy for prostate cancer.
abstract: Dendritic cells (DCs) are professional antigen-presenting cells (APCs), which display an extraordinary capacity to induce, sustain, and regulate T-cell responses providing the opportunity of DC-based cancer vaccination strategies. Thus, clinical trials enrolling prostate cancer patients were conducted, which were based on the administration of DCs loaded with tumor-associated antigens. These clinical trials revealed that DC-based immunotherapeutic strategies represent safe and feasible concepts for the induction of immunological and clinical responses in prostate cancer patients. In this context, the administration of the vaccine sipuleucel-T consisting of autologous peripheral blood mononuclear cells including APCs, which were pre-exposed in vitro to the fusion protein PA2024, resulted in a prolonged overall survival among patients with metastatic castration-resistant prostate cancer. In April 2010, sipuleucel-T was approved by the United States Food and Drug Administration for prostate cancer therapy.
authors.affiliation: Institute of Immunology, Medical Faculty, Technical University of Dresden, Fetscherstrasse 74, Dresden, Germany.
authors.forename: Hanka
authors.initials: H
authors.lastname: Jähnisch
authors.forename: Susanne
authors.initials: S
authors.lastname: Füssel
authors.forename: Andrea
authors.initials: A
authors.lastname: Kiessling
authors.forename: Rebekka
authors.initials: R
authors.lastname: Wehner
authors.forename: Stefan
authors.initials: S
authors.lastname: Zastrow
authors.forename: Michael
authors.initials: M
authors.lastname: Bachmann
authors.forename: Ernst Peter
authors.initials: EP
authors.lastname: Rieber
authors.forename: Manfred P
authors.initials: MP
authors.lastname: Wirth
authors.forename: Marc
authors.initials: M
authors.lastname: Schmitz
mesh_terms: D000135:Acid Phosphatase / Q000276:immunology / Q000378:metabolism; D000818:Animals; D000938:Antigen-Presenting Cells / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology / Q000378:metabolism; D019496:Cancer Vaccines; D002986:Clinical Trials as Topic; D003713:Dendritic Cells / Q000276:immunology*; D017277:Drug Approval; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000276:immunology / Q000378:metabolism; D006801:Humans; D016219:Immunotherapy, Adoptive; D008213:Lymphocyte Activation; D008297:Male; D011471:Prostatic Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D011993:Recombinant Fusion Proteins / Q000276:immunology / Q000378:metabolism; D014020:Tissue Extracts / Q000627:therapeutic use*; D014481:United States
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D011993:Recombinant Fusion Proteins; D014020:Tissue Extracts; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; C511774:sipuleucel-T; D000135:Acid Phosphatase; C416374:PA2024 fusion protein, human